Eisai Gets OK to Market Breast Cancer Drug in Australia

Eisai Co. announced Friday that its Australian pharmaceutical sales subsidiary, Eisai Australia Pty. Ltd., has received approval from the Australian Department of Health and Aging to market the anticancer agent Halaven.
Asahi Shimbun